Managed Care Perspectives on the Treatment and Management of Ovarian Cancer: Optimizing Outcomes with PARP Inhibitors

Managed Care Perspectives on the Treatment and Management of Ovarian Cancer: Optimizing Outcomes with PARP Inhibitors is organized by National Association of Managed Care Physicians (NAMCP).,This activity is valid from August 1, 2022, to August 1, 2023,Description:,There will be an estimated 21,410 new cases of ovarian cancer this year in the United States, and an estimated 13,770 deaths due to ovarian cancer in the US, according to the American Cancer Society. Ovarian cancer is usually found late, stage 3 or higher, where it has already spread or metastasized to other parts of the abdomen, or worse. This is due in large part to a lack of symptoms during the earlier stages. The five-year survival rate is only 45%. Fortunately for patients with ovarian cancer, the treatment paradigm has exploded in the past three years, giving medical directors and clinicians more options in managing patients with ovarian cancer. Leading the way in new options for ovarian cancer are poly (ADP-ribose) polymerase (PARP) inhibitors, which have shown improved efficacy for patients with ovarian cancer. Additionally, new indications for these targeted agents offer expanded options in the maintenance setting in varying lines of therapy. It is important for medical directors, oncologists, and nurses who manage ovarian cancer patient populations to have a solid understanding of the mechanistic rationale for the use of these medications in order to optimize their therapeutic application.,Upon completion of this activity, participants will be able to:,• Evaluate the clinical and economic burden of ovarian cancer, including factors that contribute to poor prognosis and increased costs,• Examine the clinical utility of PARP inhibitors in the management of advanced ovarian cancer, including first-line maintenance,• Compare and contrast safety and efficacy outcomes from recent pivotal trials on PARP inhibitors in ovarian cancer, both in the maintenance setting and in the setting of recurrence following prior use of platinum-based therapy,• Identify patients with advanced ovarian cancer for whom a PARP inhibitor is an appropriate choice for the next step in the management of their cancer,• Review strategies for anticipating, recognizing, and managing adverse events of PARP inhibitor therapy in patients with ovarian cancer,• Explore managed care considerations to facilitate optimal use of PARP inhibitors in advanced ovarian cancer